Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

381. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease

Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease Gaspoz J-M, Coxson P G, Goldman P A, Williams L W, Kuntz K M, Hunnink M, Goldman L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of aspirin and clopidogrel (a thienopyridine derivative) for secondary prevention in patients with coronary heart disease (CHD). Type of intervention Secondary prevention. Economic study type Cost-utility analysis. Study population The study population comprised patients over 35

NHS Economic Evaluation Database.2002

382. Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis

Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis Suleiman S, Rex D K, Sonnenberg A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology Three strategies for the prevention of colorectal cancer (CRC) were examined: colonoscopy (COL) once every 10 years or, in case of adenomatous polyps, every 3 years until polyps were no longer found; chemoprevention (CHE) with 325 mg/day aspirin; and a combination of the first and second strategies (i.e. COL every 10 or 3 years plus 325 mg/day aspirin). Type of intervention Diagnosis and primary prevention

NHS Economic Evaluation Database.2002

383. Aspirin for the primary prevention of cardiovascular events

Aspirin for the primary prevention of cardiovascular events Aspirin for the primary prevention of cardiovascular events Aspirin for the primary prevention of cardiovascular events Hayden M, Pignone M, Phillips C, Mulrow C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary (...) prevention of cardiovascular events. Rockville: Agency for Healthcare Research and Quality (AHRQ). Preventive Services Task Force Systematic Evidence Review. 2002 Authors' objectives To examine the benefits and harms of aspirin chemoprevention. Authors' conclusions Aspirin can prevent myocardial infarctions but increases the risk of gastrointestinal bleeding and appears to increase the risk of hemorrhagic stroke. The net benefit of aspirin increases with increasing cardiovascular risk. The decision about

Health Technology Assessment (HTA) Database.2002

384. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.

Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. 12087138 2002 06 27 2002 07 02 2013 11 21 1533-4406 346 26 2002 Jun 27 The New England journal of medicine N. Engl. J. Med. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. 2033-8 The role of gastric acid suppression in preventing the recurrence of ulcer complications after the eradication of Helicobacter pylori infection (...) in patients taking long-term low-dose aspirin is uncertain. We enrolled 123 patients who had ulcer complications after using low-dose aspirin continuously for more than one month and who had H. pylori infection. After the ulcers had healed and the H. pylori infection was eradicated, the patients were randomly assigned to treatment with 30 mg of lansoprazole daily or placebo, in addition to 100 mg of aspirin daily, for 12 months. The primary end point was the recurrence of ulcer complications. During

NEJM2002

385. Warfarin, aspirin, or both after myocardial infarction.

Warfarin, aspirin, or both after myocardial infarction. 12324552 2002 09 26 2002 10 02 2016 08 03 1533-4406 347 13 2002 Sep 26 The New England journal of medicine N. Engl. J. Med. Warfarin, aspirin, or both after myocardial infarction. 969-74 The role of antithrombotic therapy in secondary prevention after myocardial infarction is well established. Although the available literature suggests that warfarin is superior to aspirin, aspirin is currently the more widely used drug. We studied (...) the efficacy and safety of warfarin, aspirin, or both after myocardial infarction. In a randomized, multicenter trial in 3630 patients, 1216 received warfarin (in a dose intended to achieve an international normalized ratio [INR] of 2.8 to 4.2), 1206 received aspirin (160 mg daily), and 1208 received aspirin (75 mg daily) combined with warfarin (in a dose intended to achieve an INR of 2.0 to 2.5). The mean duration of observation was four years. The primary outcome, a composite of death, nonfatal

NEJM2002

386. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial.

Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. 12126819 2002 07 19 2002 07 30 2015 06 16 0140-6736 360 9327 2002 Jul 13 Lancet (London, England) Lancet Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. 109-13 Antiplatelet treatment with aspirin and oral anticoagulants reduces recurrence of ischaemic events after myocardial infarction. We aimed to investigate which of these drugs (...) is more effective in the long term after acute coronary events, and whether the combination of aspirin and oral anticoagulants offers greater benefit than either of these agents alone, without excessive risk of bleeding. In a randomised open-label trial in 53 sites, we randomly assigned 999 patients to low-dose aspirin, high-intensity oral anticoagulation, or combined low-dose aspirin and moderate intensity oral anticoagulation. Patients were followed up for a maximum of 26 months. The primary

Lancet2002

387. Acetaminophen, aspirin, and chronic renal failure.

Acetaminophen, aspirin, and chronic renal failure. BACKGROUND: Several epidemiologic studies have demonstrated an association between heavy consumption of nonnarcotic analgesics and the occurrence of chronic renal failure, but it is unclear which is the cause and which is the effect METHODS: In a nationwide, population-based, case-control study of early-stage chronic renal failure in Sweden, face-to-face interviews were conducted with 926 patients with newly diagnosed renal failure and 998 (...) control subjects, of whom 918 and 980, respectively, had complete data. We used logistic-regression models to estimate the relative risks of disease-specific types of chronic renal failure associated with the use of various analgesics RESULTS: Aspirin and acetaminophen were used regularly by 37 percent and 25 percent, respectively, of the patients with renal failure and by 19 percent and 12 percent, respectively, of the controls. Regular use of either drug in the absence of the other was associated

NEJM2001

388. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis.

Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. BACKGROUND: Aspirin may decrease colorectal cancer incidence, but its role as an adjunct to or substitute for screening has not been evaluated. OBJECTIVE: To examine the potential cost-effectiveness of aspirin chemoprophylaxis in relation to screening. DESIGN: Markov model. DATA SOURCES: Literature on colorectal cancer epidemiology, screening, costs, and aspirin chemoprevention (1980 (...) -1999). TARGET POPULATION: General U.S. population. TIME HORIZON: 50 to 80 years of age. PERSPECTIVE: Third-party payer. INTERVENTION: Aspirin therapy in patients screened with sigmoidoscopy every 5 years and fecal occult blood testing every year (FS/FOBT) or colonoscopy every 10 years (COLO). OUTCOME MEASURES: Discounted cost per life-year gained. RESULTS OF BASE-CASE ANALYSIS: When a 30% reduction in colorectal cancer risk was assumed, aspirin increased costs and decreased life-years because

Annals of Internal Medicine2001

389. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis.

Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis. CONTEXT: Although aspirin has been shown to reduce cardiovascular morbidity and short-term mortality following acute myocardial infarction, the association between its use and long-term all-cause mortality has not been well defined. OBJECTIVES: To determine whether aspirin is associated with a mortality benefit in stable patients with known or suspected (...) coronary disease and to identify patient characteristics that predict the maximum absolute mortality benefit from aspirin. DESIGN AND SETTING: Prospective, nonrandomized, observational cohort study conducted between 1990 and 1998 at an academic medical institution, with a median follow-up of 3.1 years. PATIENTS: Of 6174 consecutive adults undergoing stress echocardiography for evaluation of known or suspected coronary disease, 2310 (37%) were taking aspirin. Patients with significant valvular disease

JAMA2001

390. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies

Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies Garcia Rodriguez L A, Hernandez-Diaz S, de Abajo F J Authors' objectives To systematically review the literature on serious upper gastrointestinal complications (...) (UGIC) associated with aspirin use, and to evaluate the influence of dose and formulation of aspirin as well as the effect of study design. Searching MEDLINE was searched from 1990 to February 2001. The search terms used were 'anti-inflammatory nonsteroidal agents' (both overall and aspirin), 'adverse effects', and 'toxicity' combined with 'peptic ulcer', 'stomach ulcer', 'duodenal ulcer', or 'gastrointestinal diseases' (including haemorrhage and perforation). The references of previous reviews were

DARE.2001

391. Aspirin for the prevention of preeclampsia in women with abnormal uterine artery Doppler: a meta-analysis

Aspirin for the prevention of preeclampsia in women with abnormal uterine artery Doppler: a meta-analysis Aspirin for the prevention of preeclampsia in women with abnormal uterine artery Doppler: a meta-analysis Aspirin for the prevention of preeclampsia in women with abnormal uterine artery Doppler: a meta-analysis Coomarasamy A, Papaioannou S, Gee H, Khan K S Authors' objectives To assess the effect of aspirin in preventing pre-eclampsia in women identified as being at high risk (...) by an abnormal uterine artery Doppler examination in the second trimester. Searching MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched for trials published between 1966 and November 2000. A combination of search terms were used to generate two subsets of citations: one including studies of 'aspirin' ('aspirin', 'antiplatelet', 'salicyl', 'acetylsalicyl', and 'platelet aggregation inhibitors') and the other including studies of 'Doppler ultrasonography' ('ultrasonography', 'ultraso

DARE.2001

392. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer: a cost-effectiveness analysis

Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer: a cost-effectiveness analysis Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer: a cost-effectiveness analysis Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer: a cost-effectiveness analysis Ladabaum U, Chopra C L, Huang G, Scheiman J M, Chernew M E, Fendrick A M Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Aspirin (a non-steroidal anti-inflammatory drug) used as prevention therapy (chemoprevention) for sporadic colorectal cancer, as an adjunct to widely used screening strategies. The screening strategies included flexible sigmoidoscopy every 5 years and yearly faecal occult blood

NHS Economic Evaluation Database.2001

393. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. 11519503 2001 08 16 2001 08 30 2013 11 21 0028-4793 345 7 2001 Aug 16 The New England journal of medicine N. Engl. J. Med. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. 494-502 Despite current treatments, patients who have acute coronary syndromes without ST-segment elevation have high rates of major (...) vascular events. We evaluated the efficacy and safety of the antiplatelet agent clopidogrel when given with aspirin in such patients. We randomly assigned 12,562 patients who had presented within 24 hours after the onset of symptoms to receive clopidogrel (300 mg immediately, followed by 75 mg once daily) (6259 patients) or placebo (6303 patients) in addition to aspirin for 3 to 12 months. The first primary outcome--a composite of death from cardiovascular causes, nonfatal myocardial infarction

NEJM2001

394. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project.

Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. 11197445 2001 01 22 2001 03 29 2015 06 16 0140-6736 357 9250 2001 Jan 13 Lancet (London, England) Lancet Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. 89-95 In addition to the treatment of specific cardiovascular risk factors (...) , intervention which interferes with the general mechanisms of atherosclerosis could further reduce the incidence of cardiovascular events. We aimed to investigate in general practice the efficacy of antiplatelets and antioxidants in primary prevention of cardiovascular events in people with one or more major cardiovascular risk factors. We did a randomised controlled open 2x2 factorial trial to investigate low-dose aspirin (100 mg/day) and vitamin E (300 mg/day) in the prevention of cardiovascular events

Lancet2001

395. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. 11520521 2001 08 24 2001 09 20 2015 06 16 0140-6736 358 9281 2001 Aug 18 Lancet (London, England) Lancet Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. 527-33 Despite the use of aspirin, there is still a risk of ischaemic (...) events after percutaneous coronary intervention (PCI). We aimed to find out whether, in addition to aspirin, pretreatment with clopidogrel followed by long-term therapy after PCI is superior to a strategy of no pretreatment and short-term therapy for only 4 weeks after PCI. 2658 patients with non-ST-elevation acute coronary syndrome undergoing PCI in the CURE study had been randomly assigned double-blind treatment with clopidogrel (n=1313) or placebo (n=1345). Patients were pretreated with aspirin

Lancet2001

396. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial.

Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. 11551576 2001 09 11 2001 09 20 2016 11 24 0140-6736 358 9283 2001 Sep 01 Lancet (London, England) Lancet Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. 702-10 Low-molecular-weight heparins and heparinoids are superior to unfractionated heparin in the prevention and treatment of venous thromboembolism, but their safety and efficacy in acute ischaemic stroke are inadequately (...) defined. This randomised, double-blind, aspirin-controlled trial tested the safety and efficacy of treatment with high-dose tinzaparin (175 anti-Xa IU/kg daily; 487 patients), medium-dose tinzaparin (100 anti-Xa IU/kg daily; 508 patients), or aspirin (300 mg daily; 491 patients) started within 48 h of acute ischaemic stroke and given for up to 10 days. Primary intracerebral haemorrhage was excluded by computed tomography. Outcome was assessed, with treatment allocation concealed, by the modified

Lancet2001

397. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. 11752357 2001 12 25 2002 01 23 2016 08 03 0028-4793 345 25 2001 Dec 20 The New England journal of medicine N. Engl. J. Med. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. 1809-17 Patients with arthritis and vascular disease may receive both low-dose aspirin and other nonsteroidal antiinflammatory drugs. We therefore investigated potential interactions between aspirin and commonly prescribed arthritis (...) therapies We administered the following combinations of drugs for six days: aspirin (81 mg every morning) two hours before ibuprofen (400 mg every morning) and the same medications in the reverse order; aspirin two hours before acetaminophen (1000 mg every morning) and the same medications in the reverse order; aspirin two hours before the cyclooxygenase-2 inhibitor rofecoxib (25 mg every morning) and the same medications in the reverse order; enteric-coated aspirin two hours before ibuprofen (400 mg

NEJM2001

398. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.

Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. 11274623 2001 03 16 2001 04 05 2014 11 20 0028-4793 344 13 2001 Mar 29 The New England journal of medicine N. Engl. J. Med. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. 967-73 Many patients who have had upper gastrointestinal bleeding continue to take (...) low-dose aspirin for cardiovascular prophylaxis or other non-steroidal antiinflammatory drugs (NSAIDs) for musculoskeletal pain. It is uncertain whether infection with Helicobacter pylori is a risk factor for bleeding in such patients. We studied patients with a history of upper gastrointestinal bleeding who were infected with H. pylori and who were taking low-dose aspirin or other NSAIDs. We evaluated whether eradication of the infection or omeprazole treatment was more effective in preventing

NEJM2001

399. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke.

A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. 11794192 2001 11 05 2002 01 16 2014 11 20 0028-4793 345 20 2001 Nov 15 The New England journal of medicine N. Engl. J. Med. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. 1444-51 Despite the use of antiplatelet agents, usually aspirin, in patients who have had an ischemic stroke, there is still a substantial rate of recurrence. Therefore, we investigated whether warfarin (...) , which is effective and superior to aspirin in the prevention of cardiogenic embolism, would also prove superior in the prevention of recurrent ischemic stroke in patients with a prior noncardioembolic ischemic stroke. In a multicenter, double-blind, randomized trial, we compared the effect of warfarin (at a dose adjusted to produce an international normalized ratio of 1.4 to 2.8) and that of aspirin (325 mg per day) on the combined primary end point of recurrent ischemic stroke or death from any

NEJM2001

400. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis

Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis Derry S, Loke Y K Authors' objectives To assess the incidence of gastrointestinal haemorrhage associated with long-term aspirin therapy, and to determine the effect of dose reduction and formulation on the incidence of such haemorrhage. Searching Two (...) authors independently searched MEDLINE and EMBASE from 1990 to 1999 using the free text terms: 'aspirin' or 'acetylsalicylic*', or 'salicylic*'. The authors also selected trials from a list of 200 antiplatelet studies identified in a previous systematic review (see Other Publications of Related Interest), and manually checked the reference lists of retrieved studies. No language restrictions were reported. Study selection Study designs of evaluations included in the review Randomised controlled trials

DARE.2000